NAFLD in 2017

Novel insights into mechanisms of disease progression

In 2017, there have been substantial advances in our understanding of the immunological and endocrine mechanisms of disease progression in NAFLD, paving the way for novel therapeutic strategies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: NAFLD pathogenesis.


  1. 1

    Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).

    Article  Google Scholar 

  2. 2

    Wong, R. J. et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148, 547–555 (2015).

    Article  Google Scholar 

  3. 3

    Luedde, T., Kaplowitz, N. & Schwabe, R. F. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology,147 765–783.e4 (2014).

    CAS  Article  Google Scholar 

  4. 4

    Guo, L. et al. Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression. J. Clin. Invest. 127, 4449–4461 (2017).

    Article  Google Scholar 

  5. 5

    Jiang, J. et al. Circulating neuregulin 4 levels are inversely associated with subclinical cardiovascular disease in obese adults. Sci. Rep. 6, 36710 (2016).

    CAS  Article  Google Scholar 

  6. 6

    Hart, K. M. et al. Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β. Sci. Transl Med. 9, 396 (2017).

    Article  Google Scholar 

  7. 7

    Majumdar, A. et al. Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 9, 530–538 (2012).

    CAS  Article  Google Scholar 

  8. 8

    Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcioma. N. Engl. J. Med, 359, 378–390 (2008).

    CAS  Article  Google Scholar 

  9. 9

    Shalapour, S. et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551, 340–345 (2017).

    CAS  Article  Google Scholar 

  10. 10

    El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492–2502 (2017).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Philip N. Newsome.

Ethics declarations

Competing interests

P.N.N. has served as a speaker, a consultant and an advisory board member for AbbVie, Boehringer Ingelheim, Gilead, Intercept, Janssen, Novartis, Novo Nordisk, Pharmaxis and Shire, and has received research funding from these organizations on behalf of the University of Birmingham, UK. R.S.K. has received research funding from the National Institute of Health Research.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Khan, R., Newsome, P. Novel insights into mechanisms of disease progression. Nat Rev Gastroenterol Hepatol 15, 71–72 (2018).

Download citation

Further reading


Quick links

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing